{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T04:13:06Z","timestamp":1747714386564,"version":"3.40.5"},"reference-count":20,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>Bei Bronchiektasen handelt es sich immer noch um ein seltenes weiterhin noch unterdiagnostiziertes Krankheitsbild, wenngleich die Pr\u00e4valenz stetig zunimmt \u2013 mit heterogenem Patientenkollektiv, bei unterschiedlicher \u00c4tiologie. Gem\u00e4\u00df der S2k-Leitlinie vom Mai 2024 zum Management erwachsener Patienten mit Bronchiektasen-Erkrankung ist nicht mehr die Genese, sondern die Symptomatik entscheidend f\u00fcr die Definition dieser Erkrankung.<\/jats:p><jats:p>Bronchiektasien sind ein zunehmend diagnostiziertes Krankheitsbild aufgrund der vermehrten CT Thorax Untersuchungen und steigenden awareness f\u00fcr dieses Krankheitsbild, jedoch ohne bisher zugelassene spezifische Therapien au\u00dferhalb der CF (Mukoviszidose\/Cystic fibrosis). Eine Phase-3-Studie mit einem DPP1-Inhibitor zeigt ein positives Ansprechen, bei effektiver Reduktion von Exazerbationen im Vergleich zu Placebo. Es ist zu erwarten, dass das erste Medikament zur spezifischen anti-inflammatorischen Therapie au\u00dferhalb der CF noch im Laufe des Jahres 2025 eine Zulassung auf dem deutschen Markt finden wird.<\/jats:p><jats:p>Treibender Faktor f\u00fcr die Krankheitsentstehung und den Progress ist u.a. eine chronische, f\u00fchrend neutrophile, seltener auch eine eosinophile Atemwegsinflammation. Die Inflammation kann als Schl\u00fcsselfaktor f\u00fcr Symptome und Exazerbationen gesehen werden. Nach Diagnosestellung sollte die weitere \u00c4tiologie gekl\u00e4rt werden, da dies mitunter therapeutische Konsequenzen nach sich ziehen kann, wenn eine behandelbare Grunderkrankung besteht.<\/jats:p><jats:p>Wichtigste diagnostische Ma\u00dfnahme zur Detektion einer Grunderkrankung ist \u2013 neben der Anamnese \u2013 die Bildgebung mittels Computertomografie. Bei Symptomen und positiver Bildgebung spricht man von einer Bronchiektasen-Erkrankung.<\/jats:p><jats:p>Basistherapie ist die Verbesserung der mukozili\u00e4ren Clearance mittels Atemtherapie. Dar\u00fcber hinaus muss die Grunderkrankung gezielt behandelt werden sowie respiratorische Infektionen m\u00fcssen sorgf\u00e4ltig diagnostiziert und therapiert werden. Ziel ist es, Exazerbationen zu vermeiden, um so den Fortschritt der Erkrankung zu verhindern. Eine Anbindung an Expertenzentren bei manifester Bronchiektasen-Erkrankung wird aufgrund des heterogenen Krankheitsbildes, das z.T. umfassender Diagnostik und multimodaler Therapieans\u00e4tze bedarf, empfohlen.<\/jats:p>","DOI":"10.1055\/a-2145-7495","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T23:08:26Z","timestamp":1747696106000},"page":"703-712","source":"Crossref","is-referenced-by-count":0,"title":["Bronchiektasen-Erkrankung"],"prefix":"10.1055","volume":"150","author":[{"given":"Judith","family":"Smith","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Pneumologie und internistische Intensivmedizin, Uniklinik RWTH Aachen, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dreher","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Pneumologie und internistische Intensivmedizin, Uniklinik RWTH Aachen, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"03","key":"ref2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","article-title":"Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations","volume":"10","author":"S Aliberti","year":"2022","journal-title":"Lancet Respir Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105940","article-title":"Non-CF bronchiectasis: Orphan disease no longer","volume":"166","author":"JS Imam","year":"2020","journal-title":"Respir Med"},{"issue":"06","key":"ref4","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.chest.2018.07.014","article-title":"Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014","volume":"154","author":"E Henkle","year":"2018","journal-title":"Chest"},{"issue":"01","key":"ref5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12890-019-0818-6","article-title":"The economic burden of bronchiectasis \u2013 known and unknown: a systematic review","volume":"19","author":"PC Goeminne","year":"2019","journal-title":"BMC Pulm Med"},{"issue":"06","key":"ref6","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1183\/13993003.00954-2015","article-title":"Bronchiectasis in Germany: a population-based estimation of disease prevalence","volume":"46","author":"FC Ringshausen","year":"2015","journal-title":"Eur Respir J"},{"issue":"06","key":"ref7","doi-asserted-by":"publisher","first-page":"2300769","DOI":"10.1183\/13993003.00769-2023","article-title":"Transforming clinical research and science in bronchiectasis: EMBARC3, a European Respiratory Society Clinical Research Collaboration","volume":"61","author":"JD Chalmers","year":"2023","journal-title":"Eur Respir J"},{"issue":"03","key":"ref8","doi-asserted-by":"publisher","first-page":"104174","DOI":"10.1016\/j.lpm.2023.104174","article-title":"Bronchiectasis","volume":"52","author":"M Barbosa","year":"2023","journal-title":"Presse Med"},{"issue":"03","key":"ref9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"CS Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"04","key":"ref10","doi-asserted-by":"publisher","first-page":"00151","DOI":"10.1183\/23120541.00151-2024","article-title":"Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics","volume":"10","author":"JD Chalmers","year":"2024","journal-title":"ERJ Open Res"},{"issue":"03","key":"ref11","doi-asserted-by":"publisher","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"E Polverino","year":"2017","journal-title":"Eur Respir J"},{"issue":"48","key":"ref12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3238\/arztebl.2011.0809","article-title":"Bronchiectasis \u2013diagnosis and treatment","volume":"108","author":"J Rademacher","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"PA Flume","year":"2018","journal-title":"Lancet"},{"issue":"06","key":"ref14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMra2202819","article-title":"Bronchiectasis \u2013 A Clinical Review","volume":"387","author":"AE O\u2019Donnell","year":"2022","journal-title":"N Engl J Med"},{"issue":"01","key":"ref15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ccm.2021.12.002","article-title":"Allergic Bronchopulmonary Aspergillosis","volume":"43","author":"R Agarwal","year":"2022","journal-title":"Clin Chest Med"},{"issue":"05","key":"ref16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.rmed.2008.12.004","article-title":"Bronchial and peripheral airway nitric oxide in primary ciliary dyskinesia and bronchiectasis","volume":"103","author":"A Shoemark","year":"2009","journal-title":"Respir Med"},{"issue":"02","key":"ref17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccm.2012.02.002","article-title":"Bronchiectasis and nontuberculous mycobacterial disease","volume":"33","author":"DE Griffith","year":"2012","journal-title":"Clin Chest Med"},{"issue":"01","key":"ref18","doi-asserted-by":"publisher","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"CL Daley","year":"2020","journal-title":"Eur Respir J"},{"issue":"12","key":"ref19","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1164\/rccm.201910-1972OC","article-title":"Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis","volume":"201","author":"YH Gao","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"ref20","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.3390\/ijms22115996","article-title":"Protease-Antiprotease Imbalance in Bronchiectasis","volume":"22","author":"M Oriano","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"06","key":"ref22","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.chest.2018.08.1051","article-title":"New Insights Into the Epidemiology of Bronchiectasis","volume":"154","author":"JD Chalmers","year":"2018","journal-title":"Chest"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2145-7495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T23:08:38Z","timestamp":1747696118000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2145-7495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,5,19]]},"published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2145-7495","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}